GTn repeat polymorphism in heme oxygenase-1 (HO-1) correlates with clinical outcome after myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation

Research output: Contribution to journalJournal articlepeer-review

Standard

GTn repeat polymorphism in heme oxygenase-1 (HO-1) correlates with clinical outcome after myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. / Køllgaard, Tania; Kornblit, Brian; Petersen, Jesper; Klausen, Tobias Wirenfeldt; Mortensen, Bo Kok; Brændstrup, Peter; Sengeløv, Henrik; Høgdall, Estrid; Müller, Klaus; Vindeløv, Lars; Andersen, Mads Hald; thor Straten, Eivind Per.

In: PLoS ONE, Vol. 11, No. 12, e0168210, 12.2016.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Køllgaard, T, Kornblit, B, Petersen, J, Klausen, TW, Mortensen, BK, Brændstrup, P, Sengeløv, H, Høgdall, E, Müller, K, Vindeløv, L, Andersen, MH & thor Straten, EP 2016, 'GTn repeat polymorphism in heme oxygenase-1 (HO-1) correlates with clinical outcome after myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation', PLoS ONE, vol. 11, no. 12, e0168210. https://doi.org/10.1371/journal.pone.0168210

APA

Køllgaard, T., Kornblit, B., Petersen, J., Klausen, T. W., Mortensen, B. K., Brændstrup, P., Sengeløv, H., Høgdall, E., Müller, K., Vindeløv, L., Andersen, M. H., & thor Straten, E. P. (2016). GTn repeat polymorphism in heme oxygenase-1 (HO-1) correlates with clinical outcome after myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. PLoS ONE, 11(12), [e0168210]. https://doi.org/10.1371/journal.pone.0168210

Vancouver

Køllgaard T, Kornblit B, Petersen J, Klausen TW, Mortensen BK, Brændstrup P et al. GTn repeat polymorphism in heme oxygenase-1 (HO-1) correlates with clinical outcome after myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. PLoS ONE. 2016 Dec;11(12). e0168210. https://doi.org/10.1371/journal.pone.0168210

Author

Køllgaard, Tania ; Kornblit, Brian ; Petersen, Jesper ; Klausen, Tobias Wirenfeldt ; Mortensen, Bo Kok ; Brændstrup, Peter ; Sengeløv, Henrik ; Høgdall, Estrid ; Müller, Klaus ; Vindeløv, Lars ; Andersen, Mads Hald ; thor Straten, Eivind Per. / GTn repeat polymorphism in heme oxygenase-1 (HO-1) correlates with clinical outcome after myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. In: PLoS ONE. 2016 ; Vol. 11, No. 12.

Bibtex

@article{444e347a993e4ad8b144be709d7a60ee,
title = "GTn repeat polymorphism in heme oxygenase-1 (HO-1) correlates with clinical outcome after myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation",
abstract = "Allogeneic hematopoietic cell transplantation (HCT) is a treatment for various hematologic diseases where efficacy of treatment is in part based on the graft versus tumour (GVT) activity of cells in the transplant. The cytoprotective enzyme heme oxygenase-1 (HO-1) is a ratelimiting enzyme in heme degradation and it has been shown to exert anti-inflammatory functions. In humans a (GT)n repeat polymorphism regulates the expression of HO-1. We conducted fragment length analyses of the (GT)n repeat in the promotor region of the gene for HO-1 in DNA from donors and recipients receiving allogeneic myeloablative- (MA) (n = 110) or nonmyeloablative- (NMA-) (n = 250) HCT. Subsequently, we compared the length of the (GT)n repeat with clinical outcome after HCT. We demonstrated that transplants from a HO- 1high donor after MA-conditioning (n = 13) is associated with higher relapse incidence at 3 years (p = 0.01, n = 110). In the NMA-conditioning setting transplantation of HO-1low donor cells into HO-1low recipients correlated significantly with decreased relapse related mortality (RRM) and longer progression free survival (PFS) (p = 0.03 and p = 0.008, respectively). Overall, our findings suggest that HO-1 may play a role for the induction of GVT effect after allogeneic HCT.",
author = "Tania K{\o}llgaard and Brian Kornblit and Jesper Petersen and Klausen, {Tobias Wirenfeldt} and Mortensen, {Bo Kok} and Peter Br{\ae}ndstrup and Henrik Sengel{\o}v and Estrid H{\o}gdall and Klaus M{\"u}ller and Lars Vindel{\o}v and Andersen, {Mads Hald} and {thor Straten}, {Eivind Per}",
year = "2016",
month = dec,
doi = "10.1371/journal.pone.0168210",
language = "English",
volume = "11",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

RIS

TY - JOUR

T1 - GTn repeat polymorphism in heme oxygenase-1 (HO-1) correlates with clinical outcome after myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation

AU - Køllgaard, Tania

AU - Kornblit, Brian

AU - Petersen, Jesper

AU - Klausen, Tobias Wirenfeldt

AU - Mortensen, Bo Kok

AU - Brændstrup, Peter

AU - Sengeløv, Henrik

AU - Høgdall, Estrid

AU - Müller, Klaus

AU - Vindeløv, Lars

AU - Andersen, Mads Hald

AU - thor Straten, Eivind Per

PY - 2016/12

Y1 - 2016/12

N2 - Allogeneic hematopoietic cell transplantation (HCT) is a treatment for various hematologic diseases where efficacy of treatment is in part based on the graft versus tumour (GVT) activity of cells in the transplant. The cytoprotective enzyme heme oxygenase-1 (HO-1) is a ratelimiting enzyme in heme degradation and it has been shown to exert anti-inflammatory functions. In humans a (GT)n repeat polymorphism regulates the expression of HO-1. We conducted fragment length analyses of the (GT)n repeat in the promotor region of the gene for HO-1 in DNA from donors and recipients receiving allogeneic myeloablative- (MA) (n = 110) or nonmyeloablative- (NMA-) (n = 250) HCT. Subsequently, we compared the length of the (GT)n repeat with clinical outcome after HCT. We demonstrated that transplants from a HO- 1high donor after MA-conditioning (n = 13) is associated with higher relapse incidence at 3 years (p = 0.01, n = 110). In the NMA-conditioning setting transplantation of HO-1low donor cells into HO-1low recipients correlated significantly with decreased relapse related mortality (RRM) and longer progression free survival (PFS) (p = 0.03 and p = 0.008, respectively). Overall, our findings suggest that HO-1 may play a role for the induction of GVT effect after allogeneic HCT.

AB - Allogeneic hematopoietic cell transplantation (HCT) is a treatment for various hematologic diseases where efficacy of treatment is in part based on the graft versus tumour (GVT) activity of cells in the transplant. The cytoprotective enzyme heme oxygenase-1 (HO-1) is a ratelimiting enzyme in heme degradation and it has been shown to exert anti-inflammatory functions. In humans a (GT)n repeat polymorphism regulates the expression of HO-1. We conducted fragment length analyses of the (GT)n repeat in the promotor region of the gene for HO-1 in DNA from donors and recipients receiving allogeneic myeloablative- (MA) (n = 110) or nonmyeloablative- (NMA-) (n = 250) HCT. Subsequently, we compared the length of the (GT)n repeat with clinical outcome after HCT. We demonstrated that transplants from a HO- 1high donor after MA-conditioning (n = 13) is associated with higher relapse incidence at 3 years (p = 0.01, n = 110). In the NMA-conditioning setting transplantation of HO-1low donor cells into HO-1low recipients correlated significantly with decreased relapse related mortality (RRM) and longer progression free survival (PFS) (p = 0.03 and p = 0.008, respectively). Overall, our findings suggest that HO-1 may play a role for the induction of GVT effect after allogeneic HCT.

U2 - 10.1371/journal.pone.0168210

DO - 10.1371/journal.pone.0168210

M3 - Journal article

C2 - 27997582

AN - SCOPUS:85006961102

VL - 11

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 12

M1 - e0168210

ER -

ID: 180939548